Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Anthony Child

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2011
Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myelomaDavid C Johnson, Sophie L Corthals, Brian A Walker, et al.
Genes, Chromosomes & Cancer|October 1, 2011
The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapyKevin D Boyd, Fiona M Ross, William J Tapper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX StudyAndy C Rawstron, J Anthony Child, Ruth M de Tute, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Reply to M. Roschewski et alAndy C Rawstron, J Anthony Child, Ruth M de Tute, et al.
Blood|October 25, 2011
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysisGareth J Morgan, Walter M Gregory, Faith E Davies, et al.
Lancet (London, England)|December 7, 2010
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Blood|May 22, 2020
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trialsCharlotte A Bradbury, Zoe Craig, Gordon Cook, et al.
Haematologica|November 8, 2011
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial resultsGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Blood|June 10, 2011
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantationGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Blood|September 23, 2008
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotypingDavid C Johnson, Sophie Corthals, Christine Ramos, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2011
Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myelomaDavid C Johnson, Sophie L Corthals, Brian A Walker, et al.
Genes, Chromosomes & Cancer|October 1, 2011
The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapyKevin D Boyd, Fiona M Ross, William J Tapper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX StudyAndy C Rawstron, J Anthony Child, Ruth M de Tute, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Reply to M. Roschewski et alAndy C Rawstron, J Anthony Child, Ruth M de Tute, et al.
Blood|October 25, 2011
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysisGareth J Morgan, Walter M Gregory, Faith E Davies, et al.
Lancet (London, England)|December 7, 2010
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Blood|May 22, 2020
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trialsCharlotte A Bradbury, Zoe Craig, Gordon Cook, et al.
Haematologica|November 8, 2011
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial resultsGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Blood|June 10, 2011
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantationGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Blood|September 23, 2008
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotypingDavid C Johnson, Sophie Corthals, Christine Ramos, et al.
Pageof 5